Physician profile
Melissa Hakes
NPI 1659149847
$1,952.92
in general payments reported to CMS, 2019-2025
19 companies · $924 in 2025
The $924 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,029 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,952.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $398.07 | 2024-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $292.89 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $233.09 | 2024-2025 | |
| Janssen Biotech, INC. | $186.13 | 2024-2025 | Tremfya, Stelara, Erleada |
| Lilly USA, LLC | $112.36 | 2024-2025 | Omvoh |
| Pfizer INC. | $108.61 | 2024-2025 | |
| Genzyme Corporation | $97.76 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.46 | 2024-2025 | Xifaxan |
| Gilead Sciences, INC. | $71.28 | 2025 | Livdelzi |
| Merck Sharp & Dohme LLC | $61.99 | 2024 | Dificid |
| Lucid Diagnostics INC. | $44.20 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $40.60 | 2024 | Iqirvo, Bylvay |
| Medtronic, INC. | $39.45 | 2024-2025 | Pillcam, Interstim |
| Phathom Pharmaceuticals, INC. | $35.71 | 2025 | Voquezna |
| Ardelyx, INC. | $32.28 | 2025 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $30.81 | 2024 | |
| Pharmacosmos Therapeutics INC. | $28.81 | 2024 | Monoferric |
| Intercept Pharmaceuticals, INC. | $27.06 | 2024 | |
| Braintree Laboratories, INC. | $15.36 | 2024 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Hakes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.